New Market - March 31, 2018
AstraZeneca’s Lokelma approved in the EU
The European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults with hyperkalaemia. Hyperkalaemia is a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases. Lokelma is a highly-selective, oral potassium-removing agent. The approval is supported by data from three double-blind, placebo-controlled […]
New Market - March 15, 2018
NDA Group opens office in Paris
The drug development consultancy announces the opening of a Paris office to serve its increasing French customer base and in continuation of its strategic global expansion. This is NDA’s fifth European location, having offices in Stockholm, London, Munich and Zürich. The Paris office will complement the existing capabilities in other European offices to support more […]
Biotech Business - February 7, 2018
Spherotide to the Chinese market
Xbrane Biopharma and China Resource Pharmaceutical Group Limited have entered into a license agreement which gives CR Pharma exclusive rights to market and sell Spherotide (Triptorelin, a GnRH analogue in a parenteral depot formulation) in China. Swedish Xbrane will receive a license fee in high single digit million USD range paid upon signing and on milestones […]
New Market - January 22, 2018
First US order for ScandiDos
The company has received the first order for its Delta4 Discover system in the United States from The University Medical Center in Lubbock, Texas “We serve our community and safety is not just a promise, it is a priority. We look forward to informing our community that our continuing efforts to ensure safe radiation treatments have reached a new pinnacle with […]
New Market - January 19, 2018
Approval for Lynparza in Japan
AstraZeneca and Merck & Co announces that the Japanese Ministry of Health, Labour and Welfare has approved Lynparza (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy. Lynparza is the first poly ADP-ribose polymerase (PARP) inhibitor to be […]
Intellectual Property - January 10, 2018
Cantargia receives patent approval in China
The Chinese patent office, the State Intellectual Property Office, has formally approved the company’s patent application for IL1RAP as target molecule for antibody therapy of several types of solid tumours. Cantargia is developing antibodies against IL1RAP for treatment of life-threatening diseases. The company’s main project, the immuno-oncology antibody CAN04, which Nordic Life Science previously has […]
